Gigantol isomer-1

Name: Gigantol isomer-1
Brand: MedChemExpress
SKU: HY-N2523
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2523 Purity: 99.82%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Gigantol isomer-1 is a bibenzyl compound derived from Dendrobium nobile. Gigantol isomer-1 shows promising therapeutic potential against cancer cells. Gigantol isomer-1 is a novel inhibitor of the Wnt/β-catenin pathway.

For research use only. We do not sell to patients.

Gigantol isomer-1 Chemical Structure

CAS No. : 67884-30-4

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 242	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 242	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 195	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Gigantol isomer-1

•Oncotargets Ther. 2020 Nov 4;13:11337-11346. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Wnt^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HCCLM3	IC₅₀	> 100 μM Compound: 26	Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]
HepG2	IC₅₀	> 100 μM Compound: 26	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34931827]

In Vitro

Gigantol isomer-1 decreases the level of phosphorylated LRP6 and cytosolic β-catenin in HEK293 cells. In breast cancer MDA-MB-231 and MDA-MB-468 cells, treatment with Gigantol isomer-1 reduces the level of phosphorylated LRP6^[1]. Gigantol isomer-1 significantly inhibits the proliferation and induces apoptosis of the HepG2 cells. Gigantol isomer-1 at concentrations of 1, 40 and 150 μM markedly decreases the cell viability by 11.7, 30.0 and 56.4% at 24 h and 21.1, 66.8 and 85.5% at 48 h, respectively. The IC₅₀ value is 9.30 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LDD and Gigantol isomer-1 (25–100 mg/kg, p.o.) significantly increase the hot-plate latency in comparison to vehicle-treated mice and decreased carrageenaninduced inflammation in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

274.31

Formula

C₁₆H₁₈O₄

CAS No.

67884-30-4

Appearance

Solid

Color

White to off-white

SMILES

COC1=CC(O)=CC(CCC2=CC(O)=C(OC)C=C2)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (364.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (182.28 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6455 mL	18.2276 mL	36.4551 mL
5 mM	0.7291 mL	3.6455 mL	7.2910 mL
10 mM	0.3646 mL	1.8228 mL	3.6455 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.82%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (247 KB) HNMR (256 KB) LCMS (219 KB)

Handling Instructions (2659 KB)

References

[1]. Yu S, et al. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells. BMC Complement Altern Med. 2018 Feb 14;18(1):59. [Content Brief]

[2]. Chen H, et al. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 2017 Feb;37(2):865-870. [Content Brief]

[3]. Déciga-Campos M, et al. Antinociceptive and anti-inflammatory effects of compounds isolated from Scaphyglottis livida and Maxillaria densa. J Ethnopharmacol. 2007 Nov 1;114(2):161-8. [Content Brief]

Cell Assay ^[2]	HepG2 cells are treated with a series of concentrations of Gigantol (1, 10, 40, 80 and 150 µM) for different time intervals (12, 24 and 48 h). The cytotoxicity is measured using MTT assays^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Rats^[3] The anti-inflammatory activity is determined by carrageenan-induced edema test in the hind paws of rats. Sprague-Dawley rats are fasted for 15 h before the experiment with free access to water. One hundred microlitres of 1% carrageenan (10 mg/mL, Type IV, lambda) suspension is prepared 30 min before each experiment and injected into the plantar side of right hindpaw of the rats. The CH₂Cl₂-MeOH Scaphyglottis livida and Maxillaria densa extracts (150-600 mg/kg), as well as compound LDD and gigantol (25-100 mg/kg), are orally administered. The extracts, LDD and gigantol are administered 1 h before the carrageenan treatment^[3]. Mice^[3] Mice receive an oral administration of vehicle (0.2% Tween-80) or increasing doses of Scaphyglottis livida and Maxillaria densa extracts (150–600 mg/kg) or LDD and gigantol (25-100 mg/kg) 30 min before the thermal noxious stimuli in the hot-plate test. Morphine (1.5-6 mg/kg, p.o.) is used as positive control. Mice are observed before and at 30, 60, 90 and 120 min after drugs administration^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Yu S, et al. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells. BMC Complement Altern Med. 2018 Feb 14;18(1):59. [Content Brief] [2]. Chen H, et al. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 2017 Feb;37(2):865-870. [Content Brief] [3]. Déciga-Campos M, et al. Antinociceptive and anti-inflammatory effects of compounds isolated from Scaphyglottis livida and Maxillaria densa. J Ethnopharmacol. 2007 Nov 1;114(2):161-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	3.6455 mL	18.2276 mL	36.4551 mL	91.1378 mL
	5 mM	0.7291 mL	3.6455 mL	7.2910 mL	18.2276 mL
	10 mM	0.3646 mL	1.8228 mL	3.6455 mL	9.1138 mL
	15 mM	0.2430 mL	1.2152 mL	2.4303 mL	6.0759 mL
	20 mM	0.1823 mL	0.9114 mL	1.8228 mL	4.5569 mL
	25 mM	0.1458 mL	0.7291 mL	1.4582 mL	3.6455 mL
	30 mM	0.1215 mL	0.6076 mL	1.2152 mL	3.0379 mL
	40 mM	0.0911 mL	0.4557 mL	0.9114 mL	2.2784 mL
	50 mM	0.0729 mL	0.3646 mL	0.7291 mL	1.8228 mL
	60 mM	0.0608 mL	0.3038 mL	0.6076 mL	1.5190 mL
	80 mM	0.0456 mL	0.2278 mL	0.4557 mL	1.1392 mL
	100 mM	0.0365 mL	0.1823 mL	0.3646 mL	0.9114 mL